Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Lee

Showing results (391-400 of 410) with videos related to

Pageof 41
Sort By:
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Translational Oncology|October 12, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality controlEleanor Ruth Gray, Ryan Thomas Evans, Elizabeth Gillon-Zhang, et al.
Neuro-Oncology|May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoterMichael Lim, Michael Weller, Ahmed Idbaih, et al.
Gastroenterology|May 19, 2015
Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International TrialMarion-Anna Protano, Hong Xu, Guiqi Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2023
Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine-District of Columbia, August 2022Yasmin P Ogale, Nicolle Baird, Michael B Townsend, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Science (New York, N.Y.)|May 3, 2014
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytesTowfique Raj, Katie Rothamel, Sara Mostafavi, et al.
Plos One|July 25, 2015
Serum Levels of Human MIC-1/GDF15 Vary in a Diurnal Pattern, Do Not Display a Profile Suggestive of a Satiety Factor and Are Related to BMIVicky Wang-Wei Tsai, Laurence Macia, Christine Feinle-Bisset, et al.
Journal of Medicinal Chemistry|September 11, 2014
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119Dean A Wacker, Ying Wang, Matthias Broekema, et al.
Pageof 41

Showing results (391-400 of 410) with videos related to

Sort By:
Pageof 41
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Translational Oncology|October 12, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality controlEleanor Ruth Gray, Ryan Thomas Evans, Elizabeth Gillon-Zhang, et al.
Neuro-Oncology|May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoterMichael Lim, Michael Weller, Ahmed Idbaih, et al.
Gastroenterology|May 19, 2015
Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International TrialMarion-Anna Protano, Hong Xu, Guiqi Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2023
Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine-District of Columbia, August 2022Yasmin P Ogale, Nicolle Baird, Michael B Townsend, et al.
Molecular Cancer Therapeutics|March 18, 2014
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathwayPeiwen Yu, A Douglas Laird, Xiangnan Du, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Science (New York, N.Y.)|May 3, 2014
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytesTowfique Raj, Katie Rothamel, Sara Mostafavi, et al.
Plos One|July 25, 2015
Serum Levels of Human MIC-1/GDF15 Vary in a Diurnal Pattern, Do Not Display a Profile Suggestive of a Satiety Factor and Are Related to BMIVicky Wang-Wei Tsai, Laurence Macia, Christine Feinle-Bisset, et al.
Journal of Medicinal Chemistry|September 11, 2014
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119Dean A Wacker, Ying Wang, Matthias Broekema, et al.
Pageof 41